CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis

Abstract

CD44v6 has recently been reported as a biomarker for colorectal cancer. However, the clinical and prognostic significance of CD44v6 in colorectal cancer remains controversial. Therefore, we performed a meta-analysis to clarify this issue. A comprehensive literature search was performed using Medline, Embase and Web of Science, and the statistical analysis was conducted using Stata software. A total of twenty-one studies including 3918 colorectal cancer cases were included. The pooled analysis showed that CD44v6 overexpression in colorectal cancer was an independent prognostic marker correlating with lower 5-year overall survival rate (OR=0.78, 95%CI =0.67-0.91, p=0.001). CD44v6 overexpression was also associated with more lymph node invasion (OR=1.48, 95%CI= 1.02-2.15, p=0.04), and advanced Dukes stage (OR=2.47, 95%CI= 1.29-4.73, p=0.01). In addition, while excluding Zolbec's study, CD44v6 overexpression was associated with distance metastasis (OR=1.65, 95%CI =1.13-2.40, p=0.01). Taken together, this meta-analysis suggested that CD44v6 is an efficient prognostic factor in colorectal cancer.

AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer

“…Recently, a variant isoform of CD44, CD44v6, has been identified as a key CRC CSC marker that is typically overexpressed in cancer tissues (16,17). Elevated levels of CD44v6 expression are associated with poor patient prognosis in various cancers, including CRC (15,(18)(19)(20)(21)(22). Substantial overexpression of CD44v6 was observed in CRC cells overexpressing edited AZIN1 in comparison with wild-type AZIN1-overexpressing cells ( Figure 4F), providing more indication that AZIN1 RNA editing is involved in driving cancer stemness in CRC.…”

CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients’ plasma as potential noninvasive biomarkers of disease activity

“…For example, CD44v6 was identified on tumor cells in various cancer tissues, including HNSCC. [19][20][21][22] CD44v3 has been of special interest as a potential biomarker of disease progression in HNSCC, because its overexpression in HNSCC cells associates with increased proliferation, migration and a greater metastatic potential of HNSCC cancer cell lines and tumor tissues. 22,23 CD44v3 overexpression in HNSCC correlates with poor outcome, and similar associations were reported for colorectal cancer and malignant melanoma.…”

Expression of CD44v6-Containing Isoforms Influences Cisplatin Response in Gastric Cancer Cells

“…Similar results have been described in other cancer types [24,30], suggesting that expression of these variant isoforms could somehow mediate an escape mechanism to programmed cell death. In fact, expression of CD44v has been described to have a role in promoting chemoresistance through the upregulation of lyn kinase, via the Pi3K/AKT pathway in colon carcinoma cells [31] and CD44v6 in particular, was shown to block Fas mediated apoptosis [32]. The mechanism downstream of CD44v6, or cooperating with CD44v6, by which CD44v6 expressing cells have increased cisplatin survival is still unknown, however, our data show that in GC cells this may occur due to the concomitance of CD44v6 expression and activation of STAT3 or P38, depending on the cellular context.…”